ChromoGenics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
For the full year, sales was SEK 15.7 million compared to SEK 24.44 million a year ago. Revenue was SEK 19.61 million compared to SEK 29.35 million a year ago. Net loss was SEK 52.51 million compared to SEK 56.98 million a year ago. Basic loss per share from continuing operations was SEK 19.8 compared to SEK 158.8 a year ago. Diluted loss per share from continuing operations was SEK 19.8 compared to SEK 158.8 a year ago.